CARM1 and prostate adenocarcinoma: Significant variations were observed in the expression of CARM1 in various clinical phases of KIRC, PRAD, kidney renal papillary cell carcinoma (KIRP), LGG, and glioma (GBMLGG), as shown in Figure 2(b).